{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:09:51Z","timestamp":1791328191023,"version":"4.3.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T00:00:00Z","timestamp":1423094400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.revmed.2014.07.008","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T04:17:09Z","timestamp":1410927429000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Uv\u00e9ites et bioth\u00e9rapies"],"prefix":"10.1016","volume":"36","author":[{"given":"E.","family":"Feurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bielefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2014.07.008_bib0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00417-010-1485-8","article-title":"Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease","volume":"248","author":"Heiligenhaus","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.revmed.2013.10.011","article-title":"[Ocular manifestations in Beh\u00e7et's disease]","volume":"35","author":"Zeghidi","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.07.008_bib0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.revmed.2012.06.006","article-title":"[Uveitis as a presenting manifestation of sarcoidosis: clinical characteritics of a series of 23 cases]","volume":"33","author":"Pruna","year":"2012","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.07.008_bib0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2014.07.008_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2014.07.008_bib0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.revmed.2013.10.005","article-title":"[Interferon dysoric retinopathy in chronic hepatitis C. A case report and literature review]","volume":"35","author":"Na\u00efja","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.07.008_bib0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1755-3768.2011.02348.x","article-title":"Light on the horizont: biologicals in Beh\u00e7et uveitis","volume":"91","author":"Hazirolan","year":"2013","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.revmed.2014.07.008_bib0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000336324","article-title":"Interferon-\u03b1 therapy in noninfectious uveitis","volume":"51","author":"Deuter","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0055","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0060","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.revmed.2014.07.008_bib0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/09273948.2011.645989","article-title":"Interferon alpha 2b in the treatment of uveitic cystoid macular edema","volume":"20","author":"Butler","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2014.07.008_bib0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","article-title":"Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis","volume":"144","author":"Plskova","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0080","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.revmed.2013.07.006","article-title":"[Treatments with immunoglobulin and thrombotic adverse events]","volume":"35","author":"Darnige","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.07.008_bib0090","first-page":"23","article-title":"Efficacit\u00e9 et tol\u00e9rance des immunoglobulines intraveineuses dans le traitement de la r\u00e9tinochoro\u00efdopathie de type Birdshot","volume":"25","author":"Cassoux","year":"2002","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0002-9394(99)00029-X","article-title":"The treatment of refractory uveitis with intravenous immunoglobulin","volume":"127","author":"Rosenbaum","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1196\/annals.1423.036","article-title":"Human immunoglobulins in intraocular inflammation","volume":"1110","author":"Tellier","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2014.07.008_bib0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.revmed.2014.07.008_bib0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2014.07.008_bib0115","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00e7et disease","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369\u00a0patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2014.07.008_bib0135","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2014.07.008_bib0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Diaz-Llopis","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.revmed.2014.07.008_bib0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","volume":"97","author":"Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","article-title":"A three-centre experience with adalimumab for the treatment of non-infectious uveitis","volume":"97","author":"Dobner","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0160","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2014.07.008_bib0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian Registry","volume":"40","author":"Zannin","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0170","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kes373","article-title":"Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register","volume":"52","author":"Anink","year":"2013","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2014.07.008_bib0175","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2012.05.048","article-title":"Infliximab treatment of patients with birdshot retinochoroidopathy","volume":"120","author":"Artornsombudh","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2014.07.008_bib0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.revmed.2010.09.003","article-title":"Uv\u00e9ites sarco\u00efdosiques\u00a0: actualit\u00e9s diagnostiques et th\u00e9rapeutiques","volume":"32","author":"Varron","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2014.07.008_bib0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0190","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2014.07.008_bib0195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0200","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2014.07.008_bib0205","first-page":"2313","article-title":"Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab","volume":"34","author":"Sturfelt","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0210","first-page":"645","article-title":"Sarcoid-related uveitis occurring during etanercept therapy","volume":"21","author":"Hashkes","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0215","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0220","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0225","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2014.07.008_bib0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","article-title":"Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease","volume":"39","author":"Gaujoux-Viala","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0240","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis?. A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0245","first-page":"133","article-title":"L\u2019uv\u00e9e et le cristallin\u00a0: toxicit\u00e9 des nouveaux m\u00e9dicament","volume":"304","author":"Lefebvre","year":"2007","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0250","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/eye.2009.203","article-title":"Switching biologic agents for uveitis","volume":"23","author":"Dhingra","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.revmed.2014.07.008_bib0255","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2014.07.008_bib0260","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2014.07.008_bib0265","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2014.07.008_bib0270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2014.07.008_bib0275","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0280","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2014.07.008_bib0285","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2014.07.008_bib0295","first-page":"48","article-title":"[IgG4-related disease: patient group characterization and rituximab therapy]","volume":"85","author":"Sedyshev","year":"2013","journal-title":"Ter Arkhiv"},{"key":"10.1016\/j.revmed.2014.07.008_bib0300","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0310","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0315","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","article-title":"Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides","volume":"42","author":"Charles","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2014.07.008_bib0320","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0325","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0330","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","article-title":"Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis","volume":"48","author":"Yoshimura","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2014.07.008_bib0335","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2014.07.008_bib0340","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab: a novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0345","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2014.07.008_bib0350","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Beh\u00e7et's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol Jpn Rheum Assoc"},{"key":"10.1016\/j.revmed.2014.07.008_bib0355","first-page":"968180","article-title":"Refractory uveitis in patient with castleman disease successfully treated with tocilizumab","volume":"2012","author":"Oshitari","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.revmed.2014.07.008_bib0360","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0365","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0370","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et's disease with sight threatening posterior or panuveitis","volume":"87","author":"K\u00f6tter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0375","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0380","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0385","first-page":"896","article-title":"Long-term visual prognosis of patients with ocular Adamantiades-Beh\u00e7et's disease treated with interferon-alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0390","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et's uveitis refractory to conventional treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2014.07.008_bib0395","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0400","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0405","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jop.2011.0238","article-title":"Results of interferon alpha-2a therapy in patients with Behcet's disease","volume":"28","author":"Yal\u00e7inda\u011f","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.revmed.2014.07.008_bib0410","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2014.07.008_bib0415","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2014.07.008_bib0420","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2014.07.008_bib0425","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0430","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2014.07.008_bib0435","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2014.07.008_bib0440","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab therapy for the treatment of refractory ocular inflammatory disease","volume":"125","author":"Sobrin","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0445","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0450","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2014.07.008_bib0455","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2014.07.008_bib0460","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631400589X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631400589X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:33:58Z","timestamp":1759336438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886631400589X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S024886631400589X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2014.07.008","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uv\u00e9ites et bioth\u00e9rapies","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2014.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}